Drug Discovery

Drug response changes in the presence of ECM. Evaluate drug candidates in disease-relevant ECM settings IN MATRICO® that yield more predictive, in vivo-like results.

Liver ECM

MTHNLV201	Human Normal NativeCoat™ Liver ECM Coating
MTHDLV201	Human Diseased NativeCoat™ Liver ECM Coating
MTHNLV300	Human Normal TissueSpec® Liver ECM Scaffold (custom)
MTHDLV300	Human Diseased TissueSpec® Liver ECM Scaffold (custom)

Lung ECM

MTHNLG201	Human Normal NativeCoat™ Lung ECM Coating
MTHDLG201	Human Diseased NativeCoat™ Lung ECM Coating
MTHNLG300	Human Normal TissueSpec® Lung ECM Scaffold (custom)
MTHDLG300	Human Diseased TissueSpec® Lung ECM Scaffold (custom)

IN SITE™ Metastasis Kit

MTSMS101	IN SITE™ Metastasis Hydrogel Kit
MTSMS201	IN SITE™ Metastasis Surface Coating Kit

Related Resources

Application Note: Accelerating Antifibrotic Drug Development with Human Fibrotic Liver ECM Substrates

Application Note: Accelerating Antifibrotic Drug Development with Human Fibrotic Lung ECM Substrates

Application Note: IN SITE™ Metastasis Kit to Accelerate Anticancer Drug Development

Publication: Fibrotic Human Lung Extracellular Matrix as a Disease-Specific Substrate for Models of Pulmonary Fibrosis (2019)

Poster: Fibrotic Liver Extracellular Matrix Substrates for 3D in-vitro Models of Human Liver Fibrosis

Poster: Fibrotic Lung Extracellular Matrix Substrates for 3D in-vitro Models of Human Pulmonary Fibrosis

Poster: TissueSpec® Bone, Liver, and Lung ECM Substrates Enable Disease-Relevant in-vitro Models of Pre-Metastatic Tissue Microenvironments

Poster: TissueSpec® ECM Hydrogels for Predictive 3D Models of Human Cancer

Webinar: Redefining Cancer Research with IN SITE™ Metastasis Kit

Webinar: Transforming Lung Fibrosis Drug Discovery with The IN MATRICO® Human Lung Fibrosis Platform